CWHM collaborates with internal and external partners to develop and optimize target- or phenotype-based assays to identify hits that may be useful molecular probes for drug discovery programs.  Assays are tailored to project requirements and are usually conducted in 96- or 384-well formats. Partners may request screening of several available compound collections or provide their own.  Lead optimization resources are also available.